Data protection rules may block medical pr...In an effort to ban AI tools for facial recognition, the EU risks to block European medical geneticists to recognise genetic diseases. more ➔
NeuVasQ Biotechnologies bags €20m in Ser...NeuVasQ Biotechnologies has raised €20m through a Series A investment to advance its technology platform that restores the integrity of the blood-brain barrier in acute neurological disorders. more ➔ … more ➔
Coriolis Pharma expands its ATMP developme...Coriolis Pharma will launch operations at its currently expanded ATMP development facilities by Q4/2021. more ➔
mRNA: Evonik cooperates with Stanford Univ...Company seeks new opportunities for use of mRNA therapeutics. more ➔
COVAX: Pfizer and Biontech to provide 500... U.S. government to purchase at not-for-profit price 200 million doses in 2021 and 300 million in the first half of 2022. more ➔
Iksuda Therapeutics closes $47m financing... Funding to accelerate clinical progression of Iksuda’s pipeline of new generation of antibody drug conjugates, targeting tumours with high unmet need. more ➔
Lonza expands EU production capacity for M...Lonza will expand its production capacity of Modernas mRNA vaccine mRNA1273 at its manufacturing site in Geelen, the Netherlands. more ➔
EU approves Biontech/Pfizer vaccine for ad...The European Medicines Agency (EMA) has given the green light for vaccination of adolescents with Biontech’s COVID-19 vaccine Comirnaty (BNT162b2). more ➔
Senti Bio and Bluerock ink Regmed collabor...Senti Biosciences and Bayer subsidiary BlueRock Therapeutics form strategic partnership to combine iPSC and gene circuit-engineered cell therapy platforms. more ➔
Pieris in $1.4bn deal with RocheGerman-US Anticalin specialist Pieris Pharmaceuticals has bagged $20m upfront for a strategic R&D and license agreement with Genentech, the US branch of Swiss Roche AG. more ➔
